Morningstar

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and ...

GRAIL: A Major Trial Disappointment

GRAIL's topline results from the NHS-Galleri trial were a clear disappointment with no major implications on commercialization. Read why GRAL stock is a hold.
International Monetary Fund

The Business Environment and Productivity in Tanzania: Evidence from Firm Level Data

Using the World Bank’s Enterprise Surveys (ES) data, this paper sheds light on the relationship between total factor productivity (TFP) and the business environment in Tanzania. It finds statistically ...
Seeking Alpha

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

Full results published in the New England Journal of Medicine and presented at ATS 2025 International Conference BATURA builds upon the previous Phase III MANDALA and DENALI trials and in totality, ...